Thursday 18 July 1 PM (Perth Time) - 3PM (Sydney Time)
https://grafa.com/channel/asx-paradigm-biopharmaceuticals
Paradigm Biopharma is continuing to progress the regulatory review of its novel treatment for conditions including osteoarthritis and Mucopolysaccharidosis. The company is developing an injectable iPPS treatment for diseases where inflammation plays a major pathogenic role. The late stage drug development company is working towards a Phase 3 clinical trial of its iPPS treatment.
LiveStream: Paradigm Biopharma (ASX:PAR) pursuing FDA review
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |